Biopharmaceutical classification system: An account

International Journal of PharmTech Research

Volumn 2, Issue 3, 2010, Pages 1681-1690

  Yasir, Mohd ^a   Asif, Mohd ^a   Kumar, Ashwani ^a   Aggarval, Abhinav ^a  

^a DJ College of Pharmacy   (India)

Author keywords

BCS; Bioequivalence; Dissolution; Permeability; Solubility

Indexed keywords

ACICLOVIR; ALENDRONIC ACID; CAPTOPRIL; CARBAMAZEPINE; CEFUROXIME; DANAZOL; DILTIAZEM; ENALAPRIL; FELODIPINE; FUROSEMIDE; KETOCONAZOLE; KETOPROFEN; MEFENAMIC ACID; METOPROLOL; NAPROXEN; NEOMYCIN; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PHENYTOIN; TOBRAMYCIN; VERAPAMIL;

BIOEQUIVALENCE; BIOPHARMACEUTICAL CLASSIFICATION SYSTEM; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DOSE; DRUG FORMULATION; DRUG INDUSTRY; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; REVIEW;

EID: 77957555848     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Amidon GL, Lennernas H, Shah VP, and Crison JR, "A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability," Pharm. Res., 1995, 12, 413-420.
2. Guidance for industry, "Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system," CDER/FDA, August 2000.
3. Biopharmaceutics Classification System Guidance Office of Pharmaceutical Science, CDER/FDA, August 2006.
4. Dressman J, Butler J, Hempenstall J, Peppas C, "The BCS: where do we go from here," Pharmaceutical Technology., 2001, 68-76.
5. Amidon GL et al, "Estimating the fraction dose absorbed from the suspensions of poorly soluble compounds in humans: a mathematical model," Pharm Res., 1993 10(3), 264-270.
6. Dressman JB, Amidon GL, Reppas C, Shah VP, "Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms," Pharm Res., 1998 15(1): 11-22.
7. Amidon GL, Lennernas H, Shah VP, Crison JR, "A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability," Pharm. Res., 1995, 12(3), 413-419.
8. Nattee S, Natalie D, "In vitro-in vivo correlations," Int. J. Generic Drugs., 2005,250-258
9. Devane J, and Butler J, "The impact of in vitro-in vivo relationships on product development," Pharm. Tech., 1997, 21(9): 146-159.
10. Emami J, "In vitro - in vivo correlation: From theory to applications," J. Pharm. Pharmaceut. Sci., 2006, 9(2): 169-189.
11. Guidance for Industry, "Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on biopharmaceutics classification system," FDA, August 1999.
12. Swarbrick J, "Encyclopedia of pharmaceutical technology", Vol III, 3rd Edition, Pharmaceu tech inc, Informa Healthcare USA, 2007, 2049-2062.
13. Chowdary KPR, Vijayasrinivas S, "Biopharmaceutical classification system," The Indian Pharmacist, Dec 2004, 7- 10,.
14. Khar RK, Pandita D, "Biopharmaceutical classification system and its importance," The Indian Pharmacist. March 2005, 25- 30.
15. Guidance for industry, "Dissolution testing for immediate release solid oral dosage forms," FDA, August 1997.
16. Ahuja A, Baboota S, Ali J, "Dissolution: a promising tool in drug delivery," Indian J. Pharm. Sci., Nov- Dec 2005, 650-660.
17. Galia E, nicolaides E, Lobenberg RD, Dressman JB, "Evaluation of various dissolution media predicting in vivo performance of class I and Class II drugs," Pharm Res. 1998,15, 698-705.
18. USP-27th edition, NF-22nd edition, United state pharmacoepial convention, Inc., Rockville, M.D., 2004, Page No 2313-2314
19. Dressaman JB, Lennernas H, Oral drug absorption prediction and assessment, Marcel Dekker inc, Page No 159-173.
20. Macheras P, koupparis M, Apostelelli E, "Dissolution for controlled release theophylline formulations in Milk," Int. J. Pharm. 2007, 36, 73-79.
21. Ashby LJ, Beezer AE, Buckton G, "In-vitro dissolution testing of oral controlled release preparation in the presence of artificial food stuff," Int. J. Pharm., 1989,51, 245-251
22. Efentakis M, Dressman JB, "Gastric Juice as a dissolution medium: surface tension and pH," Eur. J. Drug Metab. Pharmacokinet. 1998, 23, 97-102.
23. Greenwood DE, "Small intestinal pH and buffer capacity: implications for dissolution of ionizable compounds," Doctoral dissertation, the university of Michign, Ann Arbor, MI, 1994.
24. USP-27th edition, NF-22nd edition, United state pharmacoepial convention, Inc., Rockville, M.D., 2004, Page No 2303-2312.
25. Dressaman JB, Lennernas H, "Oral drug absorption prediction and assessment," Marcel Dekker inc., Page No 174-175, 183-195
26. FIP guidelines for dissolution testing of solid oral products, Pharm Ind., 1997, 59, 760-760.
27. L Shargel, ABC Yu, "Applied biopharmaceutics and pharmacokinetics," 3rd edition, Appleton and Lange, Stamford, Connecticut, 1999. page no 365-376
28. Lennernäs H and Abrahamsson B, "The use of biopharmaceutics classification of drugs in drug discovery and development: current status and future extensions," J. Pharm. Pharmacol. 2005, 57, 273-285.
29. Aungst BJ, Intestinal permeation enhancers. J. Pharm. Sci. 2000, 89(4): 429-442.
30. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R and Frokjaer S, "Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption," Eur. J. Pharm. Sci. 2004, 21, 3-16.
31. Todd PA and Heel RC, "Enalapril a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs, 1986, 31(3): 198-248.
32. Beaumont K, Webster R, Gardner I and Dack K, "Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr. Drug Metab. 2003, 4, 461-485.
33. Bogues K, Dixon GT, Fowler P, Jenner WN, Maconochie JG, Martin LE and Willoughby BA, "Pharmacokinetics and bioavailability of ranitidine in humans," Br. J. Clin. Pharmacol. 1980, 73, 275-276.
34. Garg DC, Weidler DJ, Baltodano N, Eshelman FN, "Pharmacokinetics of ranitidine, a new histamine H2-receptor blocker," Br. J. Clin. Pharmacol.1981, 29(2): 247-248.
35. Jantratid E., Prakongpan S., Amidon G.L. and Dressman J.B., Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products cimetidine. Clin. Pharmacokinetic., 2006, 45(4): 385-399.
36. Guidance for industry,. Immediate-release solid oral dosage forms, scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalency documentation. CDER/FDA, August 1995
37. The European Agency for the Evaluation of Medicinal Products (EMEA), Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Committee for Proprietary Medicinal Products, 2002.
38. Polli JE, Yu LX, Cook JA, Amidon LA, Borchardt RT, Burnside BA, Burton PS, Chen M-L, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee VHL, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS, Wilding I and Zhang G, Summary workshop report: Biopharmaceutics classification system- implementation challenges and extension opportunities. J. Pharm. Sci.2005, 93(6): 1375-1381
39. Gupta E., Barends DM, Yamashita E, Lentz KA, Harmsze AM, Shah VP, Dressman JB and Lipper RA,. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur. J. Pharm. Sci. 2006, 26, 315-324.
40. The European Agency for the Evaluation of Medicinal Products (EMEA), Concept paper on BCS based biowaiver. Committee for Medicinal Products for Human Use, 2007
41. Barends DM, Application and experience in the EU of BCS in the review of new generics, J. Pharm.Pharmacol, 2005, 57(11): 117
42. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VHL and Hussain AS Biopharmaceutics classification system: the scientific basis for biowaiver extensions, Pharm. Res 2002,19 (7): 921-925.
43. Yazdanian M, Briggs K, Jankovsky C and Hawi A, The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs, Pharm. Res. 2004, 21(2): 293-299.
44. Rinaki E, Dokoumetzidis A, Valsami G and Macheras P,. Identification of biowaivers among class II drugs: theoretical justification and practical examples. Pharm. Res. 2004,21(9): 1567-1572.
45. Kaus LC, Gillespie WR, Hussain AS and Amidon GL, The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm. Res. 1999, 16(2): 272-280.
46. Wilson CG and Washington N, The stomach: its role in oral drug delivery. In physiological pharmaceutical: Biological barriers to drug absorption, Edited rubinstein MH, Chichester, UK, Ellis horwood: 1989, 47-70.
47. WHO, Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability, Annex 7, WHO technical report series no. 937, 2006.
48. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H., Olling M., Shah VP and Barends DM, Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system literature data: Verapamil hydrochloride, Propranolol hydrochloride, and Atenolol. J. Pharm. Sci. 2004, 93(8): 1945-1956.
49. Cheng CL., Yu LX, Lee HL., Yang CY, Lue CS and Chou CH, "Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablets", Eur. J Pharm. Sci. 2004,22: 297-304.
50. Blume HH and Schug BS, "The biopharmaceutics classification system (BCS): Class III drugs better candidates for BA/BE waiver"? Eur. J. Pharm. Sci, 1999, 9: 117-121